OSUCCC Administration, rated as """"""""Outstanding to Excellent"""""""" in 1999 and """"""""Outstanding"""""""" in 2004, is responsible for the accounting, finance, human resources, information systems, meeting planning, grants administration, document preparation, procurement, travel, marketing and facilities management required to support the operations of the OSUCCC. Since 2004, The OSUCCC Administration infrastructure has expanded from 30.6 FTEs to 59 FTEs in order to adequately support: 1) a 72% increase in NCI funding and a 35% increase in overall peer-reviewed, cancer-relevant grant funding;2) an increase in the number of shared resources, from 16 to 18 with 2 more in development;3) the recruitment of 159 new cancer faculty;4) increased inter- and intra-programmatic research activities including 41 funded and/or newly submitted POl, P50, U01, U10, SPORE and Tobacco Settlement grant applications;5) over a 274% increase in investigator-initiated clinical trial accrual;6) management of approximately 300,000 square feet of research and administration space and ongoing planning efforts for the construction of an additional 125,000 nsf of new research space by 2016;and, 7) expanded planning and evaluation activities. Overall, the responsibility of OSUCCC Administration continues to be to support and facilitate the conduct of leading-edge cancer research. The CCC administrative support offices were relocated in 2006 from space within the Martha Morehouse Medical Complex to the Ackerman facility located 0.3 miles from the OSUCCC research and medical facilities. The Ackerman facility provides 13,000 nsf (a 217% increase in space) of centralized and fully equipped office space to comfortably accommodate the large administrative team while also providing room for future growth. In addition to full tele- and videoconferencing capabilities, a continuous shuttle service provides convenient and efficient access for Administration to all OSUCCC members and staff. As detailed in the table at the end of this section, in year 1 of the 2010 CCSG renewal, we are requesting funding for 6.75 of the 59 FTEs comprising OSUCCC Administration. In dollars, the CCSG request would fund 14.8% of the total OSUCCC Administration costs with the remaining 85.2% being institutionally supported. Overall, in year 1, Administration represents 10.9% ofthe total CCSG budget request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601803
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$419,142
Indirect Cost
$144,295
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Nyankima, A Gloria; Rojas, Juan D; Cianciolo, Rachel et al. (2018) In Vivo Assessment of the Potential for Renal Bio-Effects from the Vaporization of Perfluorocarbon Phase-Change Contrast Agents. Ultrasound Med Biol 44:368-376

Showing the most recent 10 out of 2602 publications